Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is
expanding, patients' outcomes are not well documented. This study aimed to assess …

Purpose To investigate the characteristics and risk factors for neurologic adverse events
(AEs) induced by immune checkpoint inhibitors (ICIs). Methods An observational …

Background With the increased use of immune checkpoint inhibitors (ICIs) in advanced lung
cancer, adverse events (AEs), particularly immune-related AEs (irAEs), have garnered …

Immunotherapy has emerged as a powerful therapeutic approach in many areas of clinical
oncology and hematology. The approval of ipilimumab, a monoclonal antibody targeting the …

Objectives: Facial nerve palsy (or Bell's palsy) has occasionally been reported following the
administration of coronavirus disease 2019 (COVID-19) mRNA vaccines (BNT162b2 and …

Immune checkpoint inhibitors have entailed a change of paradigm in the management of
multiple malignant diseases and are acquiring a key role in an increasing number of clinical …

Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management.
Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the …

Simple Summary Our aim was to check for possible associations between clinical
parameters or NGS-based genetic alterations and the occurrence of immune-related …